statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Live webcast presentation on Thursday, April 4th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ( Autonomix or the Company ), a...

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ( Autonomix or the Company ), a...

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Autonomix Medical, Inc.

 Mrs. Jennifer Cook

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare...

Autonomix Appoints Jennifer Cook as Chief Business Officer

First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE...

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE...

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ...

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Autonomix Medical, Inc.

 Clinical Training for First Human Study

Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through...

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb...

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on July 10, 2014 and is headquartered in Doylestown, PA.

Watchers	67
52-Wk Low	$2.50
52-Wk High	$7.60

Volume	29,714.00
52-Wk High	$7.60
52-Wk Low	$2.50

AMIX Autonomix Medical Inc.

About

Feed

News

Sentiment

Fundamentals